Allergan, Drug Prices & Medicare Spending

Allergan manufactures 11 drugs tracked by Medicare Part D with total spending of $2.0B.

Drugs Tracked

$2.0B

Medicare Spending

$53.48

Avg Cost/Claim

100%

Have Generics

Allergan Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Restasis	Cyclosporine (ophthalmic)	$184.00	$456.0M	-24.6%	Yes
2	Lumigan	Bimatoprost	$94.00	$234.0M	-18.4%	Yes
3	Durysta	Bimatoprost (implant)	$944.00	$234.0M	+28.4%	Yes
4	Saphris	Asenapine	$285.00	$178.0M	-18.4%	Yes
5	Namzaric	Donepezil/Memantine	$285.00	$178.0M	-14.6%	Yes
6	Namenda	Memantine	$22.00	$145.0M	-38.6%	Yes
7	Escitalopram	Escitalopram Oxalate	$10.00	$123.0M	-32.4%	Yes
8	Memantine	Memantine Hydrochloride	$19.00	$123.0M	-24.6%	Yes
9	Bimatoprost	Bimatoprost	$66.00	$123.0M	-14.6%	Yes
10	Savella	Milnacipran	$142.00	$123.0M	-8.4%	Yes
11	Risedronate	Risedronate Sodium	$27.00	$67.0M	-22.4%	Yes

Frequently Asked Questions

Allergan manufactures 11 drugs tracked by Medicare Part D, with total annual spending of $2.0B.

Durysta (Bimatoprost (implant)) is the most expensive at $944.00 per claim.

11 of 11 Allergan drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Source: CMS Medicare Part D Spending, 2026.